Search results
-
Bristol makes its radiopharma move
… data are expected late 2025 or early 2026 . At ESMO 2023, phase 1b data from that study found a 29% overall …
- 01/03/2024 - 17:27 -
More warnings signs for ATR inhibition
… ph1/2 +/- gemcitabine/irinotecan in solid tumours at ESMO 2023 IMP9064 Impact Therapeutics First data from ph1/2 +/- senaparib in solid tumours at ESMO 2023 Camonsertib Roche (licensed from Repare) …
- 11/14/2023 - 10:58 -
ESMO 2023 movers – who won and who lost?
ESMO 2023 movers – who won and who lost? …
- 12/14/2023 - 11:53 -
ESMO 2023 – BioNTech still has work to do on Claudin6
ESMO 2023 – BioNTech still has work to do on Claudin6 … trial +/- CARVac in CLDN6+ solid tumours (NCT04503278) ESMO 2023 with automated manufacturing: 45% ORR (17/38) …
- 07/10/2024 - 10:07 -
ESMO 2023 – Nectin-4 in focus
ESMO 2023 – Nectin-4 in focus Quick …
- 10/24/2023 - 14:58 -
ESMO 2023 – how datopotamab's lung side effects are graded
ESMO 2023 – how datopotamab's lung side effects are graded …
- 10/24/2023 - 14:57 -
ESMO 2023 – red flags for PSMAfore
ESMO 2023 – red flags for PSMAfore Full …
- 10/30/2023 - 16:21 -
ESMO 2023 – Biontech’s Neon buy fails to shine
ESMO 2023 – Biontech’s Neon buy fails to shine …
- 10/23/2023 - 15:38 -
ESMO 2023 – regulators come under fire for Retevmo trial requirements
ESMO 2023 – regulators come under fire for Retevmo trial …
- 10/23/2023 - 15:37 -
ESMO 2023 – more hope for a new Car-T target
ESMO 2023 – more hope for a new Car-T target … – 1 PR (KRASm tumour) in 9 patients reported at ESMO 2023 PF-07062119 T-cell engager Pfizer …
- 10/23/2023 - 15:38
